Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets
- PMID: 1387511
- DOI: 10.1152/ajplung.1992.263.2.L249
Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets
Abstract
The neutrophil-activating peptide-2 (NAP-2) is a cytokine that is generated by the proteolytic cleavage of a precursor protein and that causes neutrophil degranulation and chemotaxis. NAP-2 precursors are produced in platelets and are normally found in the circulation. We showed that NAP-2 is generated by the action of neutrophil cathepsin G on two of the precursors, the connective tissue-activating peptide-III (CTAP-III) and beta-thromboglobulin (beta-TG). However, neutrophil elastase degraded the precursors to inactive peptides. The specific binding of cathepsin G to platelets caused the platelets to secrete NAP-2, and cathepsin G bound to the platelets could still generate NAP-2 from its precursor proteins. In addition, activated neutrophils in the presence of platelets generated NAP-2 from its precursors and caused platelets to secrete NAP-2. These studies demonstrate a unique mechanism for the activation of neutrophils through the interaction of neutrophils, platelets, and NAP-2 precursors that are released either by activated platelets or are present in circulation. It is therefore possible that NAP-2 may be generated at sites where aggregations of neutrophils and platelets occur in vessels such as pulmonary capillaries in patients with the adult respiratory distress syndrome and coronary arteries in patients with evolving myocardial infarctions.
Similar articles
-
Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases.Biochem J. 1991 May 1;275 ( Pt 3)(Pt 3):581-4. doi: 10.1042/bj2750581. Biochem J. 1991. PMID: 2039437 Free PMC article.
-
Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.J Immunol. 1994 Dec 15;153(12):5698-708. J Immunol. 1994. PMID: 7989767
-
Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.Blood. 2000 Nov 1;96(9):2965-72. Blood. 2000. PMID: 11049972
-
The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation.J Leukoc Biol. 2000 Apr;67(4):471-8. doi: 10.1002/jlb.67.4.471. J Leukoc Biol. 2000. PMID: 10770278 Review.
-
Protease actions on airway secretions. Relevance to cystic fibrosis.Ann N Y Acad Sci. 1991;624:286-96. doi: 10.1111/j.1749-6632.1991.tb17027.x. Ann N Y Acad Sci. 1991. PMID: 2064229 Review. No abstract available.
Cited by
-
Mapping of type 2 diabetes proteins to COVID-19 biomarkers: A proteomic analysis.Metabol Open. 2020 Dec 13;9:100074. doi: 10.1016/j.metop.2020.100074. eCollection 2021 Mar. Metabol Open. 2020. PMID: 33364597 Free PMC article. No abstract available.
-
Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction.Pharmaceuticals (Basel). 2017 Mar 29;10(2):36. doi: 10.3390/ph10020036. Pharmaceuticals (Basel). 2017. PMID: 28353658 Free PMC article.
-
Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x. Clin Exp Immunol. 2004. PMID: 15008987 Free PMC article.
-
Bidirectional modulation of platelet and polymorphonuclear leukocyte activities.Ann Hematol. 1993 Jul;67(1):23-31. doi: 10.1007/BF01709662. Ann Hematol. 1993. PMID: 8334196 Review. No abstract available.
-
Left ventricular remodeling in atrial fibrillation is associated with elevated NAP-2 and 3-nitrotyrosine.Biomark Med. 2025 Mar;19(5):157-164. doi: 10.1080/17520363.2025.2463882. Epub 2025 Feb 12. Biomark Med. 2025. PMID: 39935376
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous